What is it used for?
Proleukin is indicated for the treatment of adults with metastatic renal cell carcinoma (RCC). Proleukin is indicated for the treatment of adults with metastatic melanoma.Proleukin is indicated for the treatment of adults with metastatic renal cell carcinoma (RCC). Proleukin is indicated for the treatment of adults with metastatic melanoma.
Read the primary sourceThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Product details
- Active ingredient
- aldesleukinaldesleukin
- Form and strength
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · 1.1 mg / 1 mLINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · 1.1 mg / 1 mL
- Manufacturer / applicant
- IOVANCE BIOTHERAPEUTICS, INCIOVANCE BIOTHERAPEUTICS, INC
For Injection: 22 million International Units (1.3 mg) of aldesleukin available as a white to off-white, lyophilized powder in a single-dose vial for reconstitution. When reconstituted, each mL contains 18 million International Units (1.1 mg) aldesleukin.For Injection: 22 million International Units (1.3 mg) of aldesleukin available as a white to off-white, lyophilized powder in a single-dose vial for reconstitution. When reconstituted, each mL contains 18 million International Units (1.1 mg) aldesleukin.
Safety and clinical review
Capillary leak syndrome (CLS), including life threatening or fatal reactions, has occurred in patients treated with Proleukin. Do not administer Proleukin to patients with significant cardiac, pulmonary, renal, and hepatic impairment. Administer Proleukin in a hospital setting with an intensive care facility. …Capillary leak syndrome (CLS), including life threatening or fatal reactions, has occurred in patients treated with Proleukin. Do not administer Proleukin to patients with significant cardiac, pulmonary, renal, and hepatic impairment. Administer Proleukin in a hospital setting with an intensive care facility. …
- Capillary Leak SyndromeCapillary Leak Syndrome
- Neurologic ToxicityNeurologic Toxicity
- Serious Infections Including SepsisSerious Infections Including Sepsis
- Renal ToxicityRenal Toxicity
- Immune-mediated Adverse ReactionsImmune-mediated Adverse Reactions
- Embryo-Fetal ToxicityEmbryo-Fetal Toxicity
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Read the primary sourcePrepare your enquiry
Include the brand or generic name, strength, dosage form, requested quantity and country where care is needed. You can attach a prescription when you continue.
Questions patients ask
What is Proleukin used for?
Proleukin is indicated for the treatment of adults with metastatic renal cell carcinoma (RCC). Proleukin is indicated for the treatment of adults with metastatic melanoma.Proleukin is indicated for the treatment of adults with metastatic renal cell carcinoma (RCC). Proleukin is indicated for the treatment of adults with metastatic melanoma.
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Which formulation of Proleukin should I ask about?
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · 1.1 mg / 1 mLINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · 1.1 mg / 1 mL
Read the primary sourceWhat determines the price of Proleukin?
A current quote depends on the exact presentation, quantity, provider and access arrangements. A catalogue entry is not a stock or delivery promise. Medical charges are paid to the provider, separately from coordination fees.
What should I check before using Proleukin?
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Sources and review scope
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.